Spain's Almirall Launches Dermatology Digital Health Initiative
Almirall (Barcelona, Spain) has launched its first call for innovation to start-ups focused on dermatology digital health. The Almirall initiative is part of an accelerator program (the Digital Garden) to strengthen the company’s commitment to digital innovation. The winning five start-ups will be announced on November 14 at the Frontiers Health 2019 event in Berlin, Germany. The winning project teams will begin a nine-month acceleration program in January 2020 at the Barcelona Health Hub headquarters, with the objective of securing venture capital funding. In addition, the start-ups will receive up to €50K in grants, mentoring from pharma industry experts, and the opportunity to leverage leading hospitals in Barcelona as "test beds" for digital pilots. Companies can apply at almiralldigitalgarden.com almirall.com
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
